H. pylori infection
Conditions
Interventions
A group:Aneprazole + Amoxicillin
B group:Vonoprazan+ Amoxicillin+furazolidone +Bismuth
Sponsors
NanJing First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-65 years; 2. Patients with a positive 13C or 14C breath test who have not received prior H. pylori eradication therapy; 3. Voluntary enrolment and informed consent.
Exclusion criteria
Exclusion criteria: 1.Those who are allergic to the drugs used in the eradication programme; 2.Those with recent bleeding from gastroduodenal ulcers or signs of bleeding within 4 weeks; 3.Patients with prior H. pylori eradication therapy; 4.Use of antibiotics, bismuth 4 weeks prior to initiation of study treatment and histamine H2 receptor antagonists or PPIs in the first 2 weeks; 5.Use of adrenocorticotropic hormones, non-steroidal anti-inflammatory drugs or anticoagulants; 6.Previous history of oesophageal or gastric surgery; 7.Pregnant and lactating women; 8.Co-existence of other serious physical or mental illnesses, hepatic or renal insufficiency; 9.Gastric mucosa-associated lymphoid tissue lymphoma (MALT), malignant neoplastic disease. (10) Glucose-6-phosphate dehydrogenase (G-6PD) deficiency, ulcer disease or bronchial asthma; 10.Glucose-6-phosphate dehydrogenase (G-6PD) deficiency, peptic ulcer disease or bronchial asthma; 11.With the following coadministered medications: atazanavir or rilpivirine, tricyclic antidepressants, levodopa, acetaminophen, guaifenesin/dextromethorphan, monoamine oxidase inhibitors, tramadol, and others.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient compliance;Incidence of adverse reactions; | — |
Countries
China
Contacts
Public ContactZhang ZhenYu
NanJing First Hospital
Outcome results
None listed